Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

202.64 -5.40 (-2.59%)
Streaming Delayed Price Updated: 9:32 AM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗
The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics. 
Via The Motley Fool
Topics Lawsuit
News headline image
Why Natera (NTRA) Shares Are Falling Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 8.3% in the afternoon session after the release of a key inflation report revealed prices paid to U.S. producers rose more than anticipated... 
Via StockStory
Topics Earnings Economy
News headline image
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
From Natera, Inc.
Via Business Wire
News headline image
Natera (NTRA) Q4 2025 Earnings Call Transcript ↗
Natera (NTRA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Natera Inc. (NASDAQ:NTRA) Crushes Q4 Earnings Estimates with Strong Oncology Growth ↗
Via Chartmill
News headline image
Natera Reports Fourth Quarter and Full Year 2025 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera Earnings: What To Look For From NTRA
Genetic testing company Natera (NASDAQ:NTRA). will be reporting results this Thursday afternoon. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
From Natera, Inc.
Via Business Wire
News headline image
Billionaire Stanley Druckenmiller Is Betting Big on These 2 Stocks ↗
These two stocks are core holdings in the legendary investor's portfolio. 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
From Natera, Inc.
Via Business Wire
News headline image
Natera Submits Signatera™ CDx PMA to FDA
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
From Natera, Inc.
Via Business Wire
News headline image
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
From Natera, Inc.
Via Business Wire
News headline image
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting
From Natera, Inc.
Via Business Wire
News headline image
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an... 
Via MarketMinute
News headline image
Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that... 
Via MarketMinute
News headline image
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
From Natera, Inc.
Via Business Wire
News headline image
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
From Natera, Inc.
Via Business Wire
News headline image
2 Cash-Heavy Stocks to Keep an Eye On and 1 We Question
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
From Natera, Inc.
Via Business Wire
News headline image
Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
From Natera, Inc.
Via Business Wire
News headline image
The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off
As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
3 Growth Stocks with Explosive Upside
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Topics Energy
News headline image
3 Reasons We’re Fans of Natera (NTRA)
Over the past six months, Natera has been a great trade, beating the S&P 500 by 24.2%. Its stock price has climbed to $235.65, representing a healthy 37.1% increase. This was partly thanks to its solid... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.